Ghent University Academic Bibliography

Journal Article
A1
open access

Tumor Treating Fields therapy in platinum-resistant ovarian cancer : results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized study

Ignace Vergote, Larry J. Copeland, Toon Van Gorp, Annouschka Laenen, Giovanni Scambia, Premal H. Thaker, David Cibula, Nicoletta Colombo, Jayanthi Lea, Antonio Gonzalez-Martin, et al.

(2025) EUROPEAN JOURNAL OF CANCER. 219.

Add to list

Miscellaneous
open access

Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma : results of the phase II PRIMMO study (vol 72, pg 475, 2022)

Emiel De Jaeghere (UGent) , Sandra Tuyaerts, An M. T. Van Nufel, Ann Belmans, Kris Bogaerts, Regina Baiden-Amissah, Lien Lippens (UGent) , Peter Vuylsteke, Stéphanie Henry, Xuan Bich Trinh, et al.

(2024) CANCER IMMUNOLOGY IMMUNOTHERAPY. 74(1).

Add to list

Journal Article
A1
open access

Associations of the gut microbiome with outcomes in cervical and endometrial cancer patients treated with pembrolizumab : insights from the phase II PRIMMO trial

Emiel De Jaeghere (UGent) , Hannelore Hamerlinck (UGent) , Sandra Tuyaerts, Lien Lippens (UGent) , An M.T. Van Nuffel, Regina Baiden-Amissah, Peter Vuylsteke, Stéphanie Henry, Xuan Bich Trinh, Peter A. van Dam, et al.

(2024) GYNECOLOGIC ONCOLOGY. 191. p.275-286

Add to list

Journal Article
A1
open access

Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma : results of the phase II PRIMMO study

Emiel De Jaeghere (UGent) , Sandra Tuyaerts, An M. T. Van Nuffel, Ann Belmans, Kris Bogaerts, Regina Baiden-Amissah, Lien Lippens (UGent) , Peter Vuylsteke, Stéphanie Henry, Xuan Bich Trinh, et al.

(2023) CANCER IMMUNOLOGY IMMUNOTHERAPY. 72(2). p.475-491

Add to list

Conference Paper
C3
open access

Afatinib in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN) harboring alterations in the HER pathway : results of the B1 cohort of the EORTC-HNCG-1559 trial (UPSTREAM)

Rachel Galot, Christophe Le Tourneau, Lisa F. Licitra, Amaury Daste, Caroline Even, Esma Saada-Bouzid, Stephanie Henry, Sylvie Rottey (UGent) , Emmanuel Seront, Marie-Christine Kaminsky, et al.

(2023) JOURNAL OF CLINICAL ONCOLOGY. In Journal of Clinical Oncology 41(16, Supplement S).

Add to list

2022-RA-638-ESGO Pembrolizumab with multimodal immunomodulation in chemotherapy-pretreated cervical, endometrial, and uterine cancer : the PRIMMO phase II trial

Emiel De Jaeghere (UGent) , Sandra Tuyaerts, Ann M.T. van Nuffel, Ann Belmans, Kris Bogaerts, Regina Baiden-Amissah, Peter Vuylsteke, Stéphanie Henry, Xuan Bich Trinh, Peter A. van Dam, et al.

(2022) INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. In International Journal of Gynecological Cancer 32(Supplement 2). p.A187-A188

Add to list

A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck : the I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial

Rachel Galot, Christophe Le Tourneau, Esma Saada-Bouzid, Amaury Daste, Caroline Even, Philip Debruyne, Stéphanie Henry, Sylvie Zanetta, Anemie Rutten, Lisa Licitra, et al.

(2021) EUROPEAN JOURNAL OF CANCER. 158. p.17-26

Add to list

Journal Article
A1
open access

Phase 1 study evaluating the association of the cyclin-dependent kinase 4/6 inhibitor ribociclib and cetuximab in recurrent/metastatic p16-negative squamous cell carcinoma of the head and neck

Emmanuel Seront, Sandra Schmitz, Matthias Papier, Aline van Maanen, Stéphanie Henry, Christophe Lonchay, Sylvie Rottey (UGent) , Gabrielle van Caloen and Jean-Pascal Machiels

(2019) FRONTIERS IN ONCOLOGY. 9.

Add to list

Randomized phase II study of cabazitaxel versus methotrexate in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck previously treated with platinum-based therapy

Jean-Pascal Henry Machiels, Aline Van Maanen, Jean-Marie Vandenbulcke, Bertrand Filleul, Emmanuel Seront, Stéphanie Henry, Lionel D'Hondt, Christophe Lonchay, Stéphane Holbrechts, Petra Boegner, et al.

(2016) ONCOLOGIST. 21(12). p.1416-e17

Add to list

Journal Article
A1
open access

The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma

Laetitia Gerlier, Mark Lamotte, Ahmad Awada, André Bosly, Greet Bries, Veronique Cocquyt (UGent) , Christian Focan, Stephanie Henry, Yassine Lalami, Jean-Pascal Machiels, et al.

(2010) BMC CANCER. 10.

Academic Bibliography

Tumor Treating Fields therapy in platinum-resistant ovarian cancer : results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized study

Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma : results of the phase II PRIMMO study (vol 72, pg 475, 2022)

Associations of the gut microbiome with outcomes in cervical and endometrial cancer patients treated with pembrolizumab : insights from the phase II PRIMMO trial

Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma : results of the phase II PRIMMO study

Afatinib in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN) harboring alterations in the HER pathway : results of the B1 cohort of the EORTC-HNCG-1559 trial (UPSTREAM)

2022-RA-638-ESGO Pembrolizumab with multimodal immunomodulation in chemotherapy-pretreated cervical, endometrial, and uterine cancer : the PRIMMO phase II trial

A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck : the I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial

Phase 1 study evaluating the association of the cyclin-dependent kinase 4/6 inhibitor ribociclib and cetuximab in recurrent/metastatic p16-negative squamous cell carcinoma of the head and neck

Randomized phase II study of cabazitaxel versus methotrexate in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck previously treated with platinum-based therapy

The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma

Contents

Support

Contact